NICE does not recommend Opdivo (nivolumab) as a treatment for squamous NSCLC- BMS
The National Institute for Health and Care Excellence (NICE) in draft guidance has not recommended Opdivo (nivolumab) from BMS as a cost effective treatment for adult patients with locally advanced squamous NSCLC whose disease has progressed after prior chemotherapy. This rejection was made despite an offer of discount by BMS. Opdivo had shown in the CHECKMATE- 017 trial that 42% of patients with advanced squamous NSCLC were still alive at one year compared to 24% of those treated with docetaxel. The guidance is now for consultation.
Related news and insights
Medtronic plc announced three-month results from an on-label, prospective, multi-center study showing meaningful pain relief using DTM SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain.
Pfizer Inc. announced that FDA approved Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Pfizer Inc. announced positive top-line results from a Phase III study (B7471026) describing the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.